LAPTM4B Allele *2 Is Associated with Breast Cancer Susceptibility and Prognosis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Li, Xiaoyan ^a   Kong, Xiangnan ^a   Chen, Xi ^a   Zhang, Ning ^a   Jiang, Liyu ^a   Ma, Tingting ^a   Yang, Qifeng ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Key Laboratory of Digital Human and Clinical Anatomy   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4BETA; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; LAPTM4B PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CLINICAL FEATURE; CORRELATION ANALYSIS; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPTM4B GENE; LYMPH NODE METASTASIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; AGED; BIOLOGICAL MODEL; BREAST TUMOR; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, GENETIC; ONCOGENE PROTEINS; POLYMORPHISM, GENETIC; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866331132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044916     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M, (2010) Genetic susceptibility to breast cancer. Mol Oncol 4: 174-191.
3. Yu JC, Ding SL, Chang CH, Kuo SH, Chen ST, et al. (2009) Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. Carcinogenesis 30: 1562-1570.
4. Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, et al. (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22: 5060-5069.
5. Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, et al. (2003) [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. Beijing Da Xue Xue Bao 35: 340-347.
6. Liu Y, Zhang QY, Qian N, Zhou RL, (2007) Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 18: 311-316.
7. Yang H, Zhai G, Ji X, Xiong F, Su J, et al. (2012) Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol. doi:10.1007/s12032-012-0173-4.
8. Zhai G, Yang H, Ji X, Xiong F, Su J, et al. (2011) Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol. doi: 10.1007/s12032-011-0139-y.
9. Wang S, Zhang QY, Zhou RL, (2011) Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol. 23: 1864-1869.
10. Xu Y, Liu Y, Zhou R, Meng F, Gao Y, et al. (2012) LAPTM4B Polymorphisms is Associated with Ovarian Cancer Susceptibility and Its Prognosis. Jpn J Clin Oncol. 42: 413-9.
11. Meng F, Song H, Luo C, Yin M, Xu Y, et al. (2011) Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 117: 2652-2658.
12. Cheng XJ, Xu W, Zhang QY, Zhou RL, (2008) Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 19: 527-532.
13. Su P, Zhang Q, Yang Q, (2010) Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. Diagn Pathol 5: 38.
14. Zhang N, Li X, Tao K, Jiang L, Ma T, et al. (2011) BCL-2 (-938C>A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet 12: 48.
15. Rodriguez S, Gaunt TR, Day IN, (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169: 505-514.
16. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
17. Ronnov-Jessen L, Petersen OW, Bissell MJ, (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125.
18. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218.
19. Zhou L, He XD, Chen J, Cui QC, Qu Q, et al. (2007) Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer 43: 809-815.
20. Kasper G, Vogel A, Klaman I, Grone J, Petersen I, et al. (2005) The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224: 93-103.
21. Yin M, Xu Y, Lou G, Hou Y, Meng F, et al. (2011) LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 129: 629-635.
22. Zhou L, He XD, Cui QC, Zhou WX, Qu Q, et al. (2008) Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 264: 209-217.
23. Meng FL, Yin MZ, Song HT, Yang H, Lou G, et al. (2010) LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 20: 745-750.
24. Yang H, Xiong F, Qi R, Liu Z, Lin M, et al. (2010) LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 101: 363-369.
25. Yang H, Lin M, Xiong F, Yang Y, Nie X, et al. (2011) Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today 41: 810-817.
26. Yin M, Lou C, Zhang W, Meng F, Zhang H, et al. (2012) LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer 22: 54-62.
27. Li L, Wei XH, Pan YP, Li HC, Yang H, et al. (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29: 5785-5795.
28. Liu X, Xiong F, Wei X, Yang H, Zhou R, (2009) LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 100: 2335-2340.
29. Fan M, Liu Y, Zhou R, Zhang Q (2012) Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol. doi:10.1016/j.canep.2011.12.004.